ASCO submitted comments to House Energy and Commerce Committee leadership in response to a committee report entitled, “Review of the 340B Drug Pricing Program,” which examines the program and outlines recommendations to address existing challenges. ASCO appreciates the Committee’s efforts to ensure 340B honors its original intent to address the needs of low-income, underserved, and underinsured patients.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO Chief Medical Officer Richard L. Schilsky, MD, FACP, FASCO, will participate in the second annual Pediatric Precision Oncology Conference, which has extended the deadline for abstract submissions until Wednesday, February 7, 2018.
The Centers for Medicare & Medicaid Services (CMS) has updated its Extreme and Uncontrollable Circumstances policy for the 2017 Merit-based Incentive Payment System (MIPS) transition year to include counties affected by Hurricane Nate and the California wildfires.
ASCO is inviting all oncology practices to participate in the annual Survey of Oncology Practice Operations, which looks at the current state of business and operational issues in oncology.
On Jan. 26, the CancerLinQ Oncology Leadership Council convened leaders from its full coalition of public, private, and not-for-profit partners in an all-day summit to discuss CancerLinQ®—its inception, current status, and its strategic plans for the next year and beyond.
On Wednesday, January 31, the American Journal of Managed Care (AJMC) will host a webinar titled Implementing the Merit-Based Incentive Payment System for Improved Population Health.
On January 23, a congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine was published on the health effects of e-cigarettes. This report is one of the most comprehensive on e-cigarettes to-date examining over 800 peer-reviewed scientific studies.
On January 26, 2018, the Food and Drug Administration approved lutetium Lu 177 dotatate (LUTATHERA®, Advanced Accelerator Applications USA, Inc.) a radiolabeled somatostatin analog, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.
The American Society of Clinical Oncology (ASCO) congratulates Alex Azar for his confirmation as Secretary of the U.S. Department of Health and Human Services (HHS). As the head of HHS, Secretary Azar has an opportunity to help address critical issues facing the cancer care delivery system, including increasing access to high-quality care, addressing the high cost of care, and supporting the development and dissemination of innovative treatments
ASCO and 46 State and Regional Affiliates are among 109 healthcare groups urging Congress to address a rule that would penalize oncology and other medical specialties for their use of Medicare Part B drugs. The letters urge swift Congressional action, as changes to QPP that began on January 1 could negatively impact patient access critical treatments.
CancerLinQ LLC and the American College of Medical Genetics and Genomics (ACMG), the medical specialty society for clinical and laboratory genetics professionals, have entered into a programmatic collaboration.
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the agency’s proposed rulemaking revisions to the Medicare Prescription Drug Benefit Program (Part D) for 2019. ASCO applauds CMS for its efforts to advance the Part D program’s goal of promoting access to prescription drug therapies at an affordable cost to beneficiaries and urges the implementation of high-quality clinical pathways to promote access to the right drug, for the right patient, at the right time.
On January 22, the U.S. Senate and U.S. House of Representatives voted to pass a short-term Continuing Resolution (CR) to keep the federal government funded through February 8, 2018. The CR, which President Trump signed into law, ends a three-day federal government shutdown and keeps funding levels flat for federal agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI).
ASCO will host Precision Medicine: Expanding Opportunities, a robust panel discussionto focus on the United States’ challenges in precision medicine – from the overwhelming complexity of tumors, to the costs of treatment, to regulatory barriers that impede widespread use – and the solutions needed to overcome them.
ASCO published its first ASCO in Action Podcast, hosted by ASCO CEO Dr. Clifford Hudis and featuring Dr. Karen Winkfield who discusses ethnic and racial diversity in the oncology workforce, and ASCO’s strategic plan for addressing this issue.